{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '1. LIST OF ABBREVIATIONS AND DEFINITIONS OF', 'TERMS', 'Abbreviation', 'Definition', 'ACR', 'American College of Rheumatology', 'ACR20', 'American College of Rheumatology 20% response criteria', 'ACR50', 'American College of Rheumatology 50% response criteria', 'ACR70', 'American College of Rheumatology 70% response criteria', 'ADA', 'antidrug antibody', 'ADL', 'activities of daily living', 'AE', 'adverse event', 'AESI', 'adverse event of special interest', 'ALT', 'alanine aminotransferase', 'ANA', 'antinuclear antibodies', 'ApoB', 'apolipoprotein B', 'ApoAl', 'apolipoprotein Al', 'aPTT', 'activated partial thromboplastin time', 'AST', 'aspartate aminotransferase', 'ATC', 'Anatomic Therapeutic Class', 'bDMARD', 'biologic disease-modifying anti-rheumatic drug', 'BNP', 'brain natriuretic peptide', 'BP', 'blood pressure', 'CDAI', 'Clinical Disease Activity Index', 'CDC', 'Centers for Disease Control and Prevention', 'cDMARD', 'conventional disease-modifying anti-rheumatic drug', 'CDR', 'complementarity determining region', 'CMF', 'cumulative mean function', 'CRP', 'C-reactive protein', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CV', 'cardiovascular', 'CVAC', 'Cardiovascular Adjudication Committee', 'CYP', 'cytochrome P', 'DAS28', 'Disease Activity Score 28-joint Count', 'DMARD', 'disease-modifying anti-rheumatic drug', 'dsDNA', 'double-stranded DNA', 'Amendment 2: 06 March 2019', '18', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Abbreviation', 'Definition', 'DSMB', 'Data Safety Monitoring Board', 'ECG', 'electrocardiogram', 'eCRF', 'electronic case report form', 'EDC', 'Electronic Data Capture', 'EQ-5D', 'European Quality of Life-5 Dimensions', 'EQ-5D VAS', 'European Quality of Life-5 Dimensions Visual Analog Scale', 'ESR', 'erythrocyte sedimentation rate', 'EoT', 'End of Treatment', 'ER', 'event rate', 'EudraCT', 'European Clinical Trials Database', 'EULAR', 'European League Against Rheumatism', 'FACIT-Fatigue', 'Functional Assessment of Chronic Illness Therapy - Fatigue Scale', 'GCP', 'Good Clinical Practice', 'GGT', 'gamma-glutamyl transferase', 'GI', 'gastrointestinal', 'gp80', 'interleukin-6 receptor alpha chain', 'gp130', 'interleukin-6 receptor signal-transducing subunit', 'HAQ-DI', 'Health Assessment Questionnaire - Disability Index', 'HbA1c', 'glycosylated hemoglobin', 'HDL', 'high-density lipoprotein', 'HIV', 'human immunodeficiency virus', 'IA', 'intra-articular', 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation', 'IEC', 'Independent Ethics Committee', 'Ig', 'immunoglobulin', 'IGRA', 'interferon-gamma release assay', 'IL-6', 'interleukin-6', 'IL-6R', 'interleukin-6 receptor', 'IM', 'intramuscular', 'INR', 'international normalized ratio', 'IP', 'interphalangeal(s)', 'IR', 'incidence rate', 'IRB', 'Institutional Review Board', 'Amendment 2: 06 March 2019', '19', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Abbreviation', 'Definition', 'ISS', 'Integrated Summary of Safety', 'ITT', 'intent-to-treat', 'IUD', 'intrauterine device', 'IV', 'intravenous(ly', 'IWRS', 'Interactive Web Response System', 'LDL', 'low-density lipoprotein', 'LFT', 'liver function test', 'LS', 'least squares', 'mAb', 'monoclonal antibody', 'MACE', 'major adverse cardiac event', 'MCP', 'metacarpophalangeal', 'MCS', 'Mental Component Summary', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mITT', 'modified intent-to-treat', 'MTP', 'metatarsophalangeals', 'MTX', 'methotrexate', 'n', 'number of available values', 'NOAEL', 'no observed adverse effect level', 'NSAID', 'non-steroidal anti-inflammatory drugs', 'NT-proBNP', 'N-terminal pro-hormone of brain natriuretic peptide', 'OKZ', 'olokizumab', 'OLE', 'open-label extension', 'PCS', 'Physical Component Summary', 'PD', 'pharmacodynamic(s)', 'PEF', 'peak expiratory flow', 'PFS', 'pre-filled syringe(s)', 'PIP', 'proximal interphalangeals', 'PK', 'pharmacokinetic(s)', 'PP', 'Per Protocol', 'PRO', 'patient-reported outcome', 'PT', 'preferred term', 'q2w', 'once every 2 weeks', 'q4w', 'once every 4 weeks', 'QALY', 'quality-adjusted life years', 'Amendment 2: 06 March 2019', '20', 'Confidential']\n\n###\n\n", "completion": "END"}